Measurement of GABA using J-difference edited 1H-MRS following modulation of synaptic GABA concentration with tiagabine

Synapse

Volumn 68, Issue 8, 2014, Pages 355-362

  Myers, James F M ^a,b   Evans, C John ^c   Kalk, Nicola J ^a,b   Edden, Richard A E ^d   Lingford Hughes, Anne R ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GAT1; Magnetic resonance spectroscopy; MEGA PRESS

Indexed keywords

4 AMINOBUTYRIC ACID; NEUROTRANSMITTER; TIAGABINE; 4 AMINOBUTYRIC ACID CARRIER; NEUROTRANSMITTER UPTAKE INHIBITOR; NIPECOTIC ACID DERIVATIVE; SLC6A1 PROTEIN, HUMAN;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; NEUROMODULATION; NEUROTRANSMISSION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RATING SCALE; SELF REPORT; SIGNAL TRANSDUCTION; SOMNOLENCE; SYNAPSE; BRAIN; DRUG EFFECTS; EXTRACELLULAR SPACE; METABOLISM; MIDDLE AGED; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; YOUNG ADULT;

ADULT; BRAIN; EXTRACELLULAR SPACE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SYNAPSES; YOUNG ADULT;

EID: 84902286532     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21747     Document Type: Article

References (68)

1. Angehagen M, Ben-Menachem E, Ronnback L, Hansson E. 2003. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 28:333-340.
2. Axmacher N, Draguhn A. 2004. Inhibition of GABA release by presynaptic ionotropic GABA receptors in hippocampal CA3. Neuroreport 15:329-334.
3. Balazs R, Machiyama Y, Hammond BJ, Julian T, Richter D. 1970. The operation of the gamma-aminobutyrate bypath of the tricarboxylic acid cycle in brain tissue in vitro. Biochem J 116:445-461.
4. Barakat L, Bordey A. 2002. GAT-1 and reversible GABA transport in Bergmann glia in slices. J Neurophysiol 88:1407-1419.
5. Behar KL, Rothman DL, Petersen KF, Hooten M, Delaney R, Petroff OA, Shulman GI, Navarro V, Petrakis IL, Charney DS, Krystal JH. 1999. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 156:952-954.
6. Ben-Menachem E. 1995. International experience with tiagabine add-on therapy. Epilepsia 36(Suppl 6):S14-S21.
7. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, Matthews PM, Cowen PJ. 2007. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61:806-812.
8. Cai K, Nanga RP, Lamprou L, Schinstine C, Elliott M, Hariharan H, Reddy R, Epperson CN. 2012. The impact of gabapentin administration on brain GABA and glutamate concentrations: A 7T (1)H-MRS study. Neuropsychopharmacology 37:2764-2771.
9. Cammack JN, Rakhilin SV, Schwartz EA. 1994. A GABA transporter operates asymmetrically and with variable stoichiometry. Neuron 13:949-960.
10. Cavelier P, Hamann M, Rossi D, Mobbs P, Attwell D. 2005. Tonic excitation and inhibition of neurons: ambient transmitter sources and computational consequences. Prog Biophys Mol Biol 87:3-16.
11. Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. 1999. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm 27:301-323.
12. Conti F, Melone M, Fattorini G, Bragina L, Ciappelloni S. 2011. A role for GAT-1 in presynaptic GABA homeostasis? Front Cell Neurosci 5:2.
13. Dalby NO. 2003. Inhibition of gamma-aminobutyric acid uptake: Anatomy, physiology and effects against epileptic seizures. Eur J Pharmacol 479:127-137.
14. Deken SL, Wang D, Quick MW. 2003. Plasma membrane GABA transporters reside on distinct vesicles and undergo rapid regulated recycling. J Neurosci 23:1563-1568.
15. Dingledine R, Korn SJ. 1985. Gamma-aminobutyric acid uptake and the termination of inhibitory synaptic potentials in the rat hippocampal slice. J Physiol 366:387-409.
16. Donahue MJ, Near J, Blicher JU, Jezzard P. 2010. Baseline GABA concentration and fMRI response. Neuroimage 53:392-398.
17. During M, Mattson RH, Scheyer RD, Rask C, Pierce M, McKelvy J, Thomas V. 1992. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus. Epilepsia 33(Suppl 3):83.
18. Edden RA, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH. 2012. Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 69:750-753.
19. Edden RAE, Puts NA, Barker PB, Evans CJ. 2013. Gannet: GABA Analysis Toolkit for edited MRS. Proc Intl Soc Magn Reson Med 21, in press, DOI: 10.1002/jmri.24478.
20. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman DL, Krystal JH. 2002. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: A proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59:851-858.
21. Evans CJ, McGonigle DJ, Edden RA. 2010. Diurnal stability of gamma-aminobutyric acid concentration in visual and sensorimotor cortex. J Magn Reson Imaging 31:204-209.
22. Evans CJ, Puts NA, Robson SE, Boy F, McGonigle DJ, Sumner P, Singh KD, Edden RA. 2013. Subtraction artifacts and frequency (mis-)alignment in J-difference GABA editing. J Magn Reson Imaging 38:970-975.
23. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. 1992. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 220:197-201.
24. Floyer-Lea A, Wylezinska M, Kincses T, Matthews PM. 2006. Rapid modulation of GABA concentration in human sensorimotor cortex during motor learning. J Neurophysiol 95:1639-1644.
25. Foerster BR, Callaghan BC, Petrou M, Edden RA, Chenevert TL, Feldman EL. 2012a. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology 78:1596-1600.
26. Foerster BR, Petrou M, Edden RA, Sundgren PC, Schmidt-Wilcke T, Lowe SE, Harte SE, Clauw DJ, Harris RE. 2012b. Reduced insular gamma-aminobutyric acid in fibromyalgia. Arthritis Rheum 64:579-583.
27. Frankle WG, Cho RY, Mason NS, Chen CM, Himes M, Walker C, Lewis DA, Mathis CA, Narendran R. 2012. [C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels. PLoS One 7:e32443.
28. Geramita M, van der Veen JW, Barnett AS, Savostyanova AA, Shen J, Weinberger DR, Marenco S. 2011. Reproducibility of prefrontal gamma-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed 24:1089-1098.
29. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, Charney DS, Krystal JH. 2001. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58:556-561.
30. Gozzi A, Ceolin L, Schwartz A, Reese T, Crestan V, Bifone A. 2006. phMRI of brain deactivation: Effects of the antiepileptic agent tiagabine on cerebral haemodynamics. Proc Intl Soc Magn Reson Med 14:177.
31. Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H, Matsuda T. 2011. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 41:447-454.
32. Hasler G, van der Veen JW, Geraci M, Shen J, Pine D, Drevets WC. 2009. Prefrontal cortical gamma-aminobutyric acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biol Psychiatry 65:273-275.
33. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC. 2008. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 105:3628-3633.
34. Isaacson JS, Solis JM, Nicoll RA. 1993. Local and diffuse synaptic actions of GABA in the hippocampus. Neuron 10:165-175.
35. Jackson MF, Esplin B, Capek R. 1999. Inhibitory nature of tiagabine-augmented GABAA receptor-mediated depolarizing responses in hippocampal pyramidal cells. J Neurophysiol 81:1192-1198.
36. Kapogiannis D, Reiter DA, Willette AA, Mattson MP. 2013. Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network. Neuroimage 64:112-119.
37. Ke Y, Streeter CC, Nassar LE, Sarid-Segal O, Hennen J, Yurgelun-Todd DA, Awad LA, Rendall MJ, Gruber SA, Nason A, Mudrick MJ, Blank SR, Meyer AA, Knapp C, Ciraulo DA, Renshaw PF. 2004. Frontal lobe GABA levels in cocaine dependence: A two-dimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res 130:283-293.
38. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS. 2004. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45:1478-1487.
39. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, Hetherington H. 2002. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58:368-372.
40. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. 1998. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 11:266-272.
41. Micheva KD, Taylor CP, Smith SJ. 2006. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 70:467-476.
42. Mullins PG, McGonigle DJ, O'Gorman RL, Puts NA, Vidyasagar R, Evans CJ, Edden RA. 2014. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 86:43-52.
43. Muthukumaraswamy SD, Edden RA, Jones DK, Swettenham JB, Singh KD. 2009. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc Natl Acad Sci USA 106:8356-8361.
44. Muthukumaraswamy SD, Evans CJ, Edden RA, Wise RG, Singh KD. 2012. Individual variability in the shape and amplitude of the BOLD-HRF correlates with endogenous GABAergic inhibition. Hum Brain Mapp 33:455-465.
45. O'Gorman RL, Michels L, Edden RA, Murdoch JB, Martin E. 2011. In vivo detection of GABA and glutamate with MEGA-PRESS: Reproducibility and gender effects. J Magn Reson Imaging 33:1262-1267.
46. Overstreet LS, Westbrook GL. 2001. Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol 86:596-603.
47. Petroff OA, Rothman DL, Behar KL, Mattson RH. 1996a. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 46:1459-1463.
48. Petroff OA, Rothman DL, Behar KL, Mattson RH. 1996b. Low brain GABA level is associated with poor seizure control. Ann Neurol 40:908-911.
49. Petroff OA, Hyder F, Mattson RH, Rothman DL. 1999a. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 52:473-478.
50. Petroff OA, Rothman DL, Behar KL, Hyder F, Mattson RH. 1999b. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 8:120-127.
51. Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF. 2008. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry 32:739-743.
52. Puts NA, Edden RA. 2012. In vivo magnetic resonance spectroscopy of GABA: A methodological review. Prog Nucl Magn Reson Spectrosc 60:29-41.
53. Puts NA, Edden RA, Evans CJ, McGlone F, McGonigle DJ. 2011. Regionally specific human GABA concentration correlates with tactile discrimination thresholds. J Neurosci 31:16556-16560.
54. Rogawski MA. 2006. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273-294.
55. Rothman DL, Petroff OA, Behar KL, Mattson RH. 1993. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 90:5662-5666.
56. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. 1999. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56:1043-1047.
57. Stagg CJ, Best JG, Stephenson MC, O'Shea J, Wylezinska M, Kincses ZT, Morris PG, Matthews PM, Johansen-Berg H. 2009a. Polarity-sensitive modulation of cortical neurotransmitters by transcranial stimulation. J Neurosci 29:5202-5206.
58. Stagg CJ, Wylezinska M, Matthews PM, Johansen-Berg H, Jezzard P, Rothwell JC, Bestmann S. 2009b. Neurochemical effects of theta burst stimulation as assessed by magnetic resonance spectroscopy. J Neurophysiol 101:2872-2877.
59. Stagg CJ, Bachtiar V, Johansen-Berg H. 2011. What are we measuring with GABA magnetic resonance spectroscopy? Commun Integr Biol 4:573-575.
60. Suzdak PD, Jansen JA. 1995. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612-626.
61. Thompson SM, Gahwiler BH. 1992. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J Neurophysiol 67:1698-1701.
62. Waagepetersen HS, Sonnewald U, Schousboe A. 1999. The GABA paradox: Multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem 73:1335-1342.
63. Wang X, Ratnaraj N, Patsalos PN. 2004. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13:574-581.
64. Weber OM, Verhagen A, Duc CO, Meier D, Leenders KL, Boesiger P. 1999. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn Reson Imaging 17:417-425.
65. Winkelman JW, Buxton OM, Jensen JE, Benson KL, O'Connor SP, Wang W, Renshaw PF. 2008. Reduced brain GABA in primary insomnia: Preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep 31:1499-1506.
66. Wu Y, Wang W, Diez-Sampedro A, Richerson GB. 2007. Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1. Neuron 56:851-865.
67. Zaleska MM, Erecinska M. 1987. Role of sialic acid in synaptosomal transport of amino acid transmitters. Proc Natl Acad Sci USA 84:1709-1712.
68. Zhang Y, Brady M, Smith S. 2001. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 20:45-57.